FARS-ADL across Ataxias: Construct Validity, Sensitivity to Change, and Minimal Important Change
Publikation: Beitrag in Fachzeitschrift › Forschungsartikel › Beigetragen › Begutachtung
Beitragende
- Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) - Standort Tübingen
- Universitätsklinikum Tübingen
- Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) - Standort Bonn
- Universitätsklinikum Essen
- Munich Cluster for Systems Neurology (SyNergy)
- Koc University
- Universidade Federal de São Paulo
- IRCCS Fondazione Stella Maris
Abstract
BACKGROUND: Patient-focused outcomes present a central need for trial-readiness across all ataxias. The Activities of Daily Living part of the Friedreich Ataxia Rating Scale (FARS-ADL) captures functional impairment and longitudinal change but is only validated in Friedreich Ataxia.
OBJECTIVE: Validation of FARS-ADL regarding disease severity and patient-meaningful impairment, and its sensitivity to change across genetic ataxias.
METHODS: Real-world registry data of FARS-ADL in 298 ataxia patients across genotypes were analyzed, including (1) cross-correlation with FARS-stage, Scale for the Assessment and Rating of Ataxia (SARA), Patient-Reported Outcome Measure (PROM)-ataxia, and European Quality of Life 5 Dimensions visual analogue scale (EQ5D-VAS); (2) sensitivity to change within a trial-relevant 1-year median follow-up, anchored in Patient Global Impression of Change (PGI-C); and (3) general linear modeling of factors age, sex, and depression (nine-item Patient Health Questionnaire [PHQ-9]).
RESULTS: FARS-ADL correlated with overall disability (rhoFARS-stage = 0.79), clinical disease severity (rhoSARA = 0.80), and patient-reported impairment (rhoPROM-ataxia = 0.69, rhoEQ5D-VAS = -0.37), indicating comprehensive construct validity. Also at item level, and validated within genotype (SCA3, RFC1), FARS-ADL correlated with the corresponding SARA effector domains; and all items correlated to EQ5D-VAS quality of life. FARS-ADL was sensitive to change at a 1-year interval, progressing only in patients with worsening PGI-C. Minimal important change was 1.1. points based on intraindividual variability in patients with stable PGI-C. Depression was captured using FARS-ADL (+0.3 points/PHQ-9 count) and EQ5D-VAS, but not FARS-stage or SARA.
CONCLUSION: FARS-ADL reflects both disease severity and patient-meaningful impairment across genetic ataxias, with sensitivity to change in trial-relevant timescales in patients perceiving change. It thus presents a promising patient-focused outcome for upcoming ataxia trials. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Details
Originalsprache | Englisch |
---|---|
Seiten (von - bis) | 965-974 |
Seitenumfang | 10 |
Fachzeitschrift | Movement Disorders |
Jahrgang | 39 |
Ausgabenummer | 6 |
Publikationsstatus | Veröffentlicht - 20 März 2024 |
Peer-Review-Status | Ja |
Externe IDs
Scopus | 85188556989 |
---|---|
ORCID | /0000-0002-2387-526X/work/176343348 |
Schlagworte
Schlagwörter
- Activities of Daily Living, Adult, Aged, Ataxia/physiopathology, Female, Friedreich Ataxia/physiopathology, Humans, Male, Middle Aged, Minimal Clinically Important Difference, Patient Reported Outcome Measures, Quality of Life, Registries, Reproducibility of Results, Severity of Illness Index, Young Adult